Thomas Catinazzo Sells 1,800 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock
by Doug Wharley · The Cerbat GemRelay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CFO Thomas Catinazzo sold 1,800 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $15.00, for a total value of $27,000.00. Following the completion of the sale, the chief financial officer owned 213,867 shares of the company’s stock, valued at approximately $3,208,005. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Thomas Catinazzo also recently made the following trade(s):
- On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $230,498.17.
- On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The shares were sold at an average price of $8.45, for a total value of $14,322.75.
- On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total value of $105,308.40.
Relay Therapeutics Price Performance
Shares of RLAY traded up $0.49 during trading hours on Thursday, hitting $15.00. The stock had a trading volume of 3,079,104 shares, compared to its average volume of 2,889,805. The firm has a 50 day simple moving average of $9.95 and a 200-day simple moving average of $8.11. The firm has a market capitalization of $2.68 billion, a P/E ratio of -9.26 and a beta of 1.57. Relay Therapeutics, Inc. has a 1-year low of $2.07 and a 1-year high of $15.00.
Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.06. The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $4.34 million. Equities analysts predict that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.
Hedge Funds Weigh In On Relay Therapeutics
Large investors have recently bought and sold shares of the stock. Torren Management LLC bought a new position in Relay Therapeutics during the 4th quarter valued at $30,000. Smartleaf Asset Management LLC lifted its stake in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Relay Therapeutics during the 4th quarter valued at $46,000. Captrust Financial Advisors bought a new position in Relay Therapeutics during the 2nd quarter valued at $49,000. Finally, Cerity Partners LLC bought a new position in Relay Therapeutics during the 2nd quarter valued at $51,000. 96.98% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. Guggenheim increased their target price on Relay Therapeutics from $15.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Barclays increased their target price on Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday. Wells Fargo & Company increased their target price on Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, March 17th. Citizens Jmp increased their target price on Relay Therapeutics from $15.00 to $17.00 and gave the stock a “market outperform” rating in a report on Tuesday, March 17th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Relay Therapeutics in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.43.
Check Out Our Latest Analysis on Relay Therapeutics
About Relay Therapeutics
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.